# Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke

> **NCT04491695** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Capital Medical University** · enrollment: 420 (estimated)

## Conditions studied

- Acute Stroke

## Interventions

- **DRUG:** Tirofiban Hydrochloride
- **DRUG:** Oral antiplatelet

## Key facts

- **NCT ID:** NCT04491695
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-12
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04491695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04491695, "Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04491695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*